Clinical Trials
5
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
Active, not recruiting
1
20.0%
Completed
1
20.0%
Recruiting
2
40.0%
Terminated
1
20.0%
No approval data available
- Citizen Health secured $30 million in Series A funding led by 8VC to develop an AI Advocate platform for rare disease patients, bringing total funding to $44 million since December 2023. - The platform has built over 60 communities across 123 rare conditions and achieved a 98.3% patient data-sharing rate, with data already accepted by the FDA for regulatory submissions. - The company plans to launch its AI Advocate to select communities in Q3 2025, focusing on transforming fragmented healthcare into proactive, personalized patient experiences. - With rare diseases affecting over 400 million people globally and 95% lacking approved treatments, the platform addresses critical unmet needs in rare disease care and research.
- A new study reveals that genetic testing in epilepsy patients leads to changes in clinical management in approximately half of the cases. - Clinician-implemented changes based on genetic testing results in improved health outcomes for as many as 75% of patients. - Positive outcomes include a reduction, and in some cases, complete elimination of seizures, highlighting the potential of precision medicine. - The findings support universal genetic testing for all diagnosed epilepsy patients to potentially improve health outcomes and clinical decision-making.
